GSK plc’s Cytokinetics CYTK Stock Holding History

GSK plc’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29M	Hold	340,434	–	–	4.82%	6
2026 Q1	$22.4M	Hold	340,434	–	–	3.75%	7
2025 Q4	$21.6M	Buy	+340,434	New	+$21.2M	2.71%	7

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSK plc's CYTK Position: Q2 2026 in Review

GSK plc held its Cytokinetics (CYTK) position steady in Q2 2026 at 340,434 shares worth $29M. The position accounts for 4.82% of the portfolio, ranked #6.

GSK plc first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

GSK plc held 340,434 shares of Cytokinetics worth $29M as of Q2 2026.
GSK plc left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up 4.82% of GSK plc's portfolio in Q2 2026, its #6 holding.
GSK plc first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.